Advanced Cancers Clinical Trial
Official title:
An Exploratory Trial of Bilevel Positive Airway Pressure Device and High Flow Oxygen for Persistent Dyspnea in Advanced Cancer Patients
The goal of this clinical research study is to learn if specialized breathing devices reduce
the sensation of shortness of breath in patients with advanced cancer who are experiencing
shortness of breath. Researchers want to learn if these devices can help to control
shortness of breath.
The 2 devices being tested and compared are called BiPAP (bilevel positive airway pressure)
and Vapotherm.
Study Devices:
The BiPAP device is designed to help people get more air in and out of their lungs without
using as much effort as regular breathing. The air is given through a mask, and the amount
of air can be set to different levels.
The Vapotherm device is also designed to deliver air in and out of the lungs. The air is
warmed, filtered for bacteria, and then delivered through the nose using a tube under the
nostrils.
Study Groups:
If you are found to be eligible to take part in this study, you will be randomly assigned
(as in the flip of a coin) to 1 of 2 groups.
- Group 1 will receive air through BiPAP for up to 2 hours and then air through Vapotherm
for up to 2 hours.
- Group 2 will receive air through Vapotherm for up to 2 hours and then air through BiPAP
for up to 2 hours.
The study staff will help you use the devices.
If you have trouble with one of the devices, you can be switched to the other device before
the 2-hour period is over.
After using the first device, you will wait for up to 60 minutes before switching over to
the other device. This waiting period will occur no matter if you used the first device for
the full 2 hours or not.
During the waiting period, you will return to the same air delivery device and oxygen level
that you were using just before you started the study. The study staff will also be checking
to see if you are still eligible to use the second device.
Study Tests:
During the study period, your vital signs and level of air breathed out will be recorded
using a measuring device on your chest.
Before and after using the devices, you will rate how hard it is to catch your breath.
After using the second device, you will fill out a questionnaire that has questions about
which device you prefer. This should take less than 5 minutes.
Length of Study:
You will be on this study for up to 5 hours. You will be taken off study and the device will
be stopped if intolerable side effects occur while using a study device.
Use of Other Drugs:
During the 4-5 hour study period, you will not be allowed to take certain drugs for standard
care that may affect the study tests. These drugs include certain pain-killer drugs (such as
morphine and hydromorphone), steroids (such as prednisone and dexamethasone), and inhaled
drugs (such as ipratropium and salbutamol).
Any doses of inhaled drugs (regularly scheduled doses and "as needed" doses) and any "as
needed" doses of pain-killer drugs and steroids that fall within the 4-5 hour study period
will be put on hold and will be given to you right after the study is complete.
You may, however, choose to take these drugs, either because your shortness of breath is not
controlled, or because these drugs are needed to treat other problems (such as pain). If you
and your doctor decide that you should take these drugs during the study period, you will be
taken off study so you can receive these drugs. The reason for stopping your study
participation is that these drugs may affect how you rate your shortness of breath.
This is an investigational study. The BIPAP and Vapotherm devices are commercially available
and FDA approved for delivering oxygen when medically needed, including in patients with
advanced cancer. The investigational part of this study is to collect information from
asking patients to rate how well the study devices may affect shortness of breath.
Up to 50 patients will be enrolled in this study. All will be enrolled at MD Anderson.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01213238 -
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab
|
Phase 1 | |
Recruiting |
NCT02160366 -
Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients
|
||
Completed |
NCT00903708 -
LY2275796 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00379353 -
The Effects of Thalidomide on Symptom Clusters
|
Phase 2 | |
Terminated |
NCT00499382 -
Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging
|
N/A | |
Completed |
NCT02459964 -
Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain
|
Phase 4 | |
Completed |
NCT01430572 -
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
|
Phase 1 | |
Completed |
NCT02561234 -
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01375114 -
The Effects of Ginseng on Cancer-Related Fatigue
|
Phase 2 | |
Completed |
NCT01454804 -
Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors
|
Phase 1 | |
Completed |
NCT01201694 -
Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L)
|
Phase 1 | |
Completed |
NCT02801045 -
Art Therapy in Palliative Care: Study of Identification and Understanding of the Mechanisms of Change in the Patient
|
N/A | |
Completed |
NCT02873975 -
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency
|
Phase 2 | |
Completed |
NCT01983969 -
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT02272595 -
Rational Therapeutics Based on Matched Tumor and Normal Tissue
|
||
Active, not recruiting |
NCT01999491 -
A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma
|
Phase 1 | |
Recruiting |
NCT03375983 -
Plasmodium Immunotherapy for Advanced Cancers
|
Phase 1/Phase 2 | |
Completed |
NCT02571036 -
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
|
Phase 1 | |
Withdrawn |
NCT01608139 -
Study of Curcumin, Vorinostat, and Sorafenib
|
Phase 1 | |
Completed |
NCT01024166 -
Patient-Reported Outcomes-Based Palliative and Hospice Care Practice: A Usability Study
|
N/A |